Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1993-08-02
1997-04-22
Ivy, C. Warren
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
546155, 546157, A61K 3147, C07D21522, C07D21538
Patent
active
056229658
ABSTRACT:
Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions and inducing anesthesia are disclosed by administering to an animal in need of such treatment a substituted or unsubstituted 4-hydroxy-3-nitro-1,2-dihydroquinolin-2-one or pharmaceutically acceptable salts thereof which have high binding to the glycine receptor.
REFERENCES:
patent: 3652571 (1972-03-01), Sturm
patent: 3891653 (1975-06-01), Dreikorn
patent: 3962445 (1976-06-01), Buckle
patent: 4031099 (1977-06-01), Buckle
patent: 4032528 (1977-06-01), Hardtmann
patent: 4065457 (1977-12-01), Buckle
patent: 4190659 (1980-02-01), Hardtmann
patent: 4192876 (1980-03-01), Hardtmann
patent: 4218448 (1980-08-01), Aldrich et al.
patent: 4251534 (1981-02-01), Aldrich et al.
patent: 4909829 (1990-03-01), Theodoridis
patent: 4988815 (1991-01-01), Andre et al.
patent: 5028707 (1991-07-01), Nichols et al.
patent: 5376748 (1994-12-01), Carling et al.
McQuaid, J Med Chem, vol. 35, pp. 3423-3425, 1992.
Haley, Brain Research, vol. 518, pp. 218-226, 1990.
Boast, Brain Research, vol. 442, pp. 345-348, 1988.
Dickenson, Neurosc Lett, vol. 121, pp. 263-266, 1991.
Tricklebank, Eur J of Pharm, vol. 167, pp. 127-135, 1989.
Schoepp, J Neural Transm, vol. 85, pp. 131-143, 1991.
Buckle et al., "4-Hydroxy-3-nitrocarbostyrils and their pharmaceutical use," Chem. Abstr. 82:139976j (1975).
Boast et al., "The N-methyl-D-aspartate antagonists CGS 19755 and CPP reduce ischemic brain damage in gerbils", Brain Res. 442:345-348 (1988).
Brady et al., "Stereoisomers of N-Allylnormetazocine: Phencyclidine-Like Behavioral Effects in Squirrrel Monkeys and Rats", Science 215:178-180 (Jan. 1982).
Buckle et al., "4-Hydroxy-3-nitro-2-quinolones and Related Compounds as Inhibitors of Allergic Reactions", J. Med. Chem. 18:726-732 (1975).
Dickenson & Aydar, "Antagonism at the glycine site on the NMDA receptor reduces spinal nociception in the rat", Neuroscience Lett. 121:263-266 (1991).
Haley et al., "Evidence for spinal N-methyl-D-aspartate receptor involvement in prolonged chemical nociception in the rat", Brain Res. 518:218-226 (1990).
Johnson & Ascher, "Glycine potentiates the NMDA response in cultured mouse brain neurons", Nature 325:529-531 (Feb. 1987).
Kemp et al., "7-Chlorokynurenic acid is a selective antagonist at the glycine modulatory site of the N-methyl-D-aspartate receptor complex", Proc. Natl. Acad. Sci. USA 85:6547-6550 (Sep. 1988).
Koek et al., "MK-801, A Proposed Noncompetitive Antagonist of Excitatory Amino Acid Neurotransmission, Produces Phencyclidine-Like Behavioral Effects in Pigeons, Rats, and Rhesus Monkeys", J. Pharmacol. & Exp. Ther. 245:969-974 (1988).
McQaid et al., "3-Phenyl-4-hydroxyquinolin-2(1H)-ones: Potent and Selective Antagonists at the Strychnine-Insensitive Glycine Site on the N-Methyl-D-aspartate Receptor Complex", J. Med. Chem. 35:3423-3425 (1992).
Patel & Mehta, "Synthesis of 2,4-Dihydroxyquinolines Using Polyphosphoric Acid as the Cyclizing Agent", J. Sci. Industr. Res. 19B:436-438 (Nov. 1960).
Schoepp et al., "Neuroprotectant effects of LY 274614, a structurally novel systemically active competitive NMDA receptor antagonist", J. Neural. Trans. 85:131-143 (1991).
Skilling et al., "Differential Effects of C- and N-Terminal Substance P Metabolites on the Release of Amino Acid Neurotransmitters from the Spinal Cord: Potential Role in Nociception", J. Neurosci. 10:1309-1318 (Apr. 1990).
Tricklebank et al., "A role for receptors of N-methyl-D-aspartic acid in the discriminative stimulus properties of phencyclidine", Eur. J. Pharmacol. 141:497-501 (1987).
Tricklebank et al., "The behavioural effects of MK-801: a comparison with antagonists acting non-competitively and competitively at the NMDA receptor", Eur. J. Pharmacol. 167:127-135 (1989).
Willetts & Balster, "The Discriminative stimulus effects of N-Methyl-D-Aspartate Antagonists in Phencyclidine-Trained Rats", Neuropharmacology 27:1249-1256 (1988).
Zukin et al., "Behavioral and biochemical stereoselectivity of sigma opiate/PCP receptors", Brain Res. 294:174-177 (1984).
Lipton, New Engl. J. Med., vol. 30, pp. 613-622, 1994.
Cai Sui X.
Keana John F. W.
Weber Eckard
Ivy C. Warren
M. Mach D. Margaret
State of Oregon acting by and through The Oregon State Board of
The Regents of the University of California
LandOfFree
4-hydroxy-3-nitro-1,2-dihydroquinolin-2-ones and the use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 4-hydroxy-3-nitro-1,2-dihydroquinolin-2-ones and the use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 4-hydroxy-3-nitro-1,2-dihydroquinolin-2-ones and the use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-341912